A Fixed Dose, Dose-response Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment to L-dopa in Patients With Advanced Parkinson's Disease.
Phase of Trial: Phase IV
Latest Information Update: 14 Jul 2017
At a glance
- Drugs Ropinirole (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms TANDEM-569
- Sponsors GlaxoSmithKline
- 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Jul 2012 Actual initiation date (Apr 2012) added as reported by ClinicalTrials.gov.